Implication of embB Gene Mutation in Ethambutol-Susceptible Clinical Isolates of Mycobacterium tuberculosis / 결핵및호흡기질환
Young-Kil PARK; Sonya SHIN; Sang-Jae KIM; Won-Jung KOH; O-Jung KWON; Bum-Jun KIM; Yoon-Ho KOOK; Sang-Nae CHO; Woo-Jin LEW; Gill-Han BAI.
Tuberculosis and Respiratory Diseases
; : 266-271, 2005.
Artículo
en Inglés
| WPRIM | ID: wpr-25287
BACKGROUND:
Ethambutol(EMB) is one of the first-line drugs included in short-course anti-tuberculosis therapy. The point mutations in embB gene have been speculated to be associated EMB resistance. However, detection of embB mutations at these positions have been observed in both EMB-susceptible isolates; thus, it remains controversial whether these mutations are associated with EMB resistanceMETHODS:
The 36 M. tuberculosis isolates were selected from clinical isolates which tested susceptible to EMB and resistant to at least one drug. DNA extracted from the isolates was analyzed by amplifying embB gene. The PCR products were purified and directly sequenced. We reviewed the history of past drug susceptibility test results.RESULTS:
Out of 36 EMB-susceptible strains, 3 strains (8.3%) had a mutation in codon 306 or 406 of the embB gene. These three strains had at least isoniazid resistance. They grew at 1.0 mcg/ml of EMB in Lowenstein-Jensen media. The patients of the strains were continuously smear-positive for over 3 years despite taking TB therapy. One strain had been EMB-resistant in past drug susceptibility tests.CONCLUSION:
EMB-susceptible strains containing embB mutation may be caused by decreased viability in vitro test not by itself.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados